Wednesday, October 27, 2021
wellness India Expo
Home Tags DCGI

Tag: DCGI

Covaxin gets nod for kids aged 2-18 years

The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group

LifeCell’s therapy to treat COVID-19 patients gets DCGI nod for clinical...

New therapy derived from mesenchymal stem cells of the umbilical cord tissue set to treat patients suffering from COVID 19 pneumonia and acute respiratory distress.............................

India’s first mRNA-based Covid-19 vaccine gets DCGI nod for Phase II...

The trial for India’s first mRNA-based vaccine from Gennova Biopharmaceuticals was found to be safe in Phase I study. Post Drugs Controller General of India approval, Phase II and Phase III trials are to commence in early September, 2021......................

DCGI gives approval to anti-COVID drug ‘Colchicine’ for phase 2 clinical...

Drugs Controller General of India (DCGI) has given approval to a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients...........................

Biophore applies for DCGI emergency use approval of Aviptadil for COVID-19

Aviptadil has shown significant results in clinical trials against COVID-19. Biophore has developed both the API and the formulation in-house...........................

Sun Pharma to market Ferring Pharmaceuticals’s obstetric drug ‘CARITEC’ in India

As per the company, CARITEC is an innovative obstetric drug for preventing post-partum hemorrhage. It is a Room Temperature Stable (RTS) formulation of Carbetocin and addresses limitations in refrigeration and cold-chain transportation.......................

DCGI green signal to COVAXIN’s Phase II/III clinical trial in 2-18...

Hyderabad based Bharat Biotech to conduct clinical trials in 525 healthy volunteers........................

Roche gets DCGI nod for its investigational antibody cocktail in India

Casirivimab and Imdevimab is indicated for the treatment of mild to moderate Covid-19 in high-risk patients........................

Zydus’s COVID-19 drug ‘Virafin’ gets DCGI nod

91.15% of patients treated with PegIFN were RT PCR negative by day 7. A single dose of the antiviral Virafin administered subcutaneously early on shows significant clinical and virological improvement in moderate COVID-19 adult patients.......................

Sputnik V vaccine authorized in India

India has become the 60th country to approve the Russian vaccine, Sputnik V, one of only three vaccines registered so far in the country.........................